clinical datauniQure falls as Huntington’s gene therapy shows mixed resultsuniQure’s shares fell about 40% in early trading on September 29 after its Huntington’s gene therapy missed statistical significance on the main disease progression measure after four years. The … more ➔
fundraisingAnaCardio raises €62.5M to test heart failure drugSwedish biotech AnaCardio has raised €62.5 million to take its oral heart failure drug AC01 through Phase 2b, testing whether early improvements in pumping function hold up in a larger patient pop … more ➔
startupsAptadir secures €40M for gene-reactivating RNA drugsAptadir Therapeutics has raised €40 million in seed funding to advance an RNA therapy designed to reactivate the gene silenced in Fragile X syndrome. more ➔
fundingBreye raises €67.5M for diabetic eye disease trial with Novo Holdings backingDanish biotech Breye Therapeutics has raised €67.5 million to advance an oral eye disease drug candidate into a Phase 2 clinical trial. more ➔
anti-obesityNovo pays up to $2.6B for Hengrui’s once-weekly obesity pill candidateNovo Nordisk will pay China’s Jiangsu Hengrui Pharmaceuticals $300 million (€264 million) upfront, in a deal worth up to $2.6 billion (€2.3 billion), for rights outside Greater China to HRS-1596, … more ➔
WatchlistSix Spanish biotech startups to watch in 2026The 2025 AseBio Report shows a Spanish biotech ecosystem that is not only expanding, but attracting capital at a new scale: Spain counted 1,119 dedicated biotech companies in 2025, up 10.4% year on year, … more ➔
RegulatoryFDA keeps Newron’s evenamide trial on hold in U.S.Newron Pharmaceuticals will expand its Phase 3 evenamide trial outside the U.S. after the FDA decided to maintain a hold on enrollment at American sites. more ➔
licensingAddex regains rights to addiction drug candidate from IndiviorSwiss biotech Addex Therapeutics has regained global rights to a GABA-B drug portfolio from Indivior, including a candidate for substance use disorders that has completed studies needed before a Phase … more ➔
Drug developmentNovo licenses Nanexa’s long-acting injection platform in €1.165B dealSweden’s Nanexa has granted Novo Nordisk a global license to use its PharmaShell drug delivery technology in up to five programs targeting obesity, type 2 diabetes and other cardiometabolic diseases. … more ➔
AppointmentsBavarian Nordic names new CEO; Abivax and ProQR add key leadersEvery Friday, The Leadership Edit looks at the people taking new roles across European biotech and what their moves may tell us about the companies they join. We’ll follow chief executives, scientific … more ➔
